Observation As a Treatment Strategy for Advanced Renal Cell Carcinoma-a Call for Prospective Validation

Overview

Journal Front Oncol

Specialty Oncology

Date 2012 Nov 3

PMID 23120744

Citations 7

Authors

Rosalie Fisher

Alexandra Pender

Kiruthikah Thillai

Simon Chowdhury

Lisa Pickering

Komel Khabra

Martin Gore

James Larkin

Affiliations

Soon will be listed here.

Citing Articles

Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre.

Stares M, Chauhan V, Moudgil-Joshi J, Kong Q, Malik J, Sundaramurthy A Cancer Med. 2022; 12(5):5255-5264.

PMID: 36207803 PMC: 10028026. DOI: 10.1002/cam4.5330.

Role of metastasectomy in the management of renal cell carcinoma.

Mikhail M, Chua K, Khizir L, Tabakin A, Singer E Front Surg. 2022; 9:943604.

PMID: 35965871 PMC: 9372304. DOI: 10.3389/fsurg.2022.943604.

Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic.

Wallis C, Novara G, Marandino L, Bex A, Kamat A, Karnes R Eur Urol. 2020; 78(1):29-42.

PMID: 32414626 PMC: 7196384. DOI: 10.1016/j.eururo.2020.04.063.

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.

Rini B, Dorff T, Elson P, Suarez Rodriguez C, Shepard D, Wood L Lancet Oncol. 2016; 17(9):1317-24.

PMID: 27498080 PMC: 9199453. DOI: 10.1016/S1470-2045(16)30196-6.

Contemporary Treatment of Metastatic Renal Cell Carcinoma.

Stukalin I, Alimohamed N, Heng D Oncol Rev. 2016; 10(1):295.

PMID: 27471582 PMC: 4943094. DOI: 10.4081/oncol.2016.295.

References

Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C . Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27(34):5794-9. DOI: 10.1200/JCO.2008.21.4809. View

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

Ratain M, Eisen T, Stadler W, Flaherty K, Kaye S, Rosner G . Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24(16):2505-12. DOI: 10.1200/JCO.2005.03.6723. View

Cole B, Gelber R, Gelber S, Mukhopadhyay P . A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat. 2004; 14(1):111-24. DOI: 10.1081/BIP-120028509. View

Gore M, Szczylik C, Porta C, Bracarda S, Bjarnason G, Oudard S . Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009; 10(8):757-63. DOI: 10.1016/S1470-2045(09)70162-7. View